AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows:

1. (Currently Amended) A surgically implantable drug delivery system, comprising ~~consisting essentially of~~ (a) a biodegradable polymer or copolymer, wherein said biodegradable polymer or copolymer consists essentially of ~~selected from the group consisting of~~ polylactide or ~~and~~ lactide-co-glycolide copolymer; and (b) 20 to 40% haloperidol fabricated into an individual, surgically implantable implant via solvent casting and compression molding at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for the individual, surgically implantable implant which is surgically implanted underneath the skin of a patient, delivers steady state concentrations of haloperidol to the patient for 5 months or more and is removable from the patient in the event the patient exhibits unwanted side effects following implantation.

2. Canceled.

3. (Currently Amended) The surgically implantable drug delivery system of claim 1, wherein the biodegradable polymer or copolymer is 50-100% polylactide and 0-50[[-100]]% polyglycolide.

4. (Currently Amended) A method of producing an individual, surgically implantable implant which is surgically implanted underneath the skin of a patient for delivery of steady state concentrations of haloperidol to the patient for 5 months or more comprising: (a) dissolving haloperidol and a biodegradable polymer consisting

essentially of ~~selected from the group consisting of~~ polylactide or ~~and~~ lactide-co-glycolide copolymer in acetone; (b) solvent casting the haloperidol and biodegradable polymer solution to produce a completely dry haloperidol-polymer material; and (c) molding under compression the dry haloperidol-polymer material at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for the individual, surgically implantable implant which is surgically implanted underneath the skin of a patient, delivers steady state concentrations of haloperidol to the patient for 5 months or more, and is removable following implantation into a patient in the event the patient exhibits unwanted side effects following implantation.

5. Canceled.

6. (Original) The method of claim 4 wherein the biodegradable polymer comprises 50-100% polylactide and 0-50% polyglycolide.

7. (Original) A method for treating patients with psychotic conditions and diseases comprising surgically implanting into a patient suffering from a psychotic condition or disease the surgically implantable drug delivery system of claim 1.

8. (Original) The method of claim 7 wherein the surgically implantable drug delivery system is implanted under the skin of a patient between the muscle and the dermis.

9. (Original) The method of claim 7 wherein the patient is suffering from schizophrenia.

10. (Original) The method of claim 7 further comprising administering to the patient an antipsychotic drug orally.